Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103]

Affiliations

• ¹ Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France; Department of Medical Oncology, Institut Curie, Paris, France.
• ² Uveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, Paris, France.
• ³ Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.
• ⁴ Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
• ⁵ Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
• ⁶ Uveal Melanoma Translational Group, Department of Translational Research, Institut Curie, PSL Research University, Paris, France. Electronic address: [email protected].